AU2009223501A1 - Treatment for ocular-related disorders - Google Patents

Treatment for ocular-related disorders Download PDF

Info

Publication number
AU2009223501A1
AU2009223501A1 AU2009223501A AU2009223501A AU2009223501A1 AU 2009223501 A1 AU2009223501 A1 AU 2009223501A1 AU 2009223501 A AU2009223501 A AU 2009223501A AU 2009223501 A AU2009223501 A AU 2009223501A AU 2009223501 A1 AU2009223501 A1 AU 2009223501A1
Authority
AU
Australia
Prior art keywords
compound
ocular
formula
agents
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009223501A
Other languages
English (en)
Inventor
Ramalinga Dharanipragada
Timothy A. Gillespy
Chang Hahn
Ellen Matzkin
Thomas Oligino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of AU2009223501A1 publication Critical patent/AU2009223501A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AU2009223501A 2008-03-10 2009-03-05 Treatment for ocular-related disorders Abandoned AU2009223501A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3507308P 2008-03-10 2008-03-10
US61/035,073 2008-03-10
PCT/US2009/036119 WO2009114373A1 (en) 2008-03-10 2009-03-05 Treatment for ocular-related disorders

Publications (1)

Publication Number Publication Date
AU2009223501A1 true AU2009223501A1 (en) 2009-09-17

Family

ID=40583469

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009223501A Abandoned AU2009223501A1 (en) 2008-03-10 2009-03-05 Treatment for ocular-related disorders

Country Status (22)

Country Link
EP (1) EP2285378A1 (es)
JP (1) JP2011513488A (es)
KR (1) KR20110009084A (es)
CN (1) CN101965188A (es)
AR (1) AR070975A1 (es)
AU (1) AU2009223501A1 (es)
BR (1) BRPI0909659A2 (es)
CA (1) CA2717991A1 (es)
CL (1) CL2009000551A1 (es)
CO (1) CO6290691A2 (es)
CR (1) CR11644A (es)
DO (1) DOP2010000266A (es)
IL (1) IL207906A0 (es)
MA (1) MA32211B1 (es)
MX (1) MX2010008308A (es)
NI (1) NI201000131A (es)
NZ (1) NZ587906A (es)
RU (1) RU2010141560A (es)
SV (1) SV2010003658A (es)
TW (1) TW200950784A (es)
WO (1) WO2009114373A1 (es)
ZA (1) ZA201005337B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1990343B1 (en) * 1999-12-24 2012-04-04 Aventis Pharma Limited Azaindoles
WO2001062252A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.

Also Published As

Publication number Publication date
EP2285378A1 (en) 2011-02-23
NI201000131A (es) 2011-09-29
CA2717991A1 (en) 2009-09-17
SV2010003658A (es) 2011-01-31
DOP2010000266A (es) 2010-09-30
NZ587906A (en) 2011-12-22
KR20110009084A (ko) 2011-01-27
TW200950784A (en) 2009-12-16
CR11644A (es) 2010-11-22
CO6290691A2 (es) 2011-06-20
JP2011513488A (ja) 2011-04-28
MX2010008308A (es) 2010-08-11
BRPI0909659A2 (pt) 2015-09-22
AR070975A1 (es) 2010-05-19
CL2009000551A1 (es) 2009-08-21
RU2010141560A (ru) 2012-04-20
IL207906A0 (en) 2010-12-30
WO2009114373A1 (en) 2009-09-17
MA32211B1 (fr) 2011-04-01
CN101965188A (zh) 2011-02-02
ZA201005337B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
JP5875191B2 (ja) Ｃｍｔ及び関連障害を処置するための新たな組成物
JP2018109043A (ja) Ｃｍｔ及び関連疾患の処置のための新規な治療的アプローチ
JP5404045B2 (ja) 神経および非神経痛を治療する方法
KR101663998B1 (ko) 샤르코-마리-투스 질환 및 관련 장애를 치료하기 위한 필로카핀 및 메티마졸 조합
Zhang et al. Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex
US20130225603A1 (en) Mdm2 inhibitors for treatment of ocular conditions
KR101953736B1 (ko) 제브라피시 모델을 사용한 약물 스크리닝 방법 및 이 방법으로 스크린된 화합물
US20210401776A1 (en) Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
JPH10236978A (ja) 中枢カンナビノイドレセプターｃｂ１の既知の作用薬の利用
WO2009135091A1 (en) Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
AU2008251742A1 (en) Inhibitors of acetyl-CoA carboxylase for treatment of neuronal hypometabolism
JP2004532809A (ja) ホスホジエステラーゼ４型を阻害することによって、神経系の再生および修復を刺激するための方法
US20220226270A1 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
JP2000514402A (ja) Ｖｅｇｆに関連する目の病気に関する治療処置
JP2018521113A (ja) ＡｐｏＥ４対立遺伝子の存在を決定した後のＰＫＣ活性化因子を使用した神経変性状態の治療
TW201605443A (zh) 治療ｘ染色體脆折症及相關病症的方法
JP2021521263A (ja) 眼疾患を治療するための脱メチル化
AU2009223501A1 (en) Treatment for ocular-related disorders
US20110112101A1 (en) Treatment for ocular-related disorders
Sharif et al. Human trabecular meshwork cells express functional serotonin-2A (5HT2A) receptors: role in IOP reduction
Lan et al. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival
US20120100229A1 (en) Treatment and Prevention of White Matter Injury with KATP Channel Activators
CN101293831B (zh) 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途
JP6522641B2 (ja) 機械的な神経損傷を処置するための新規組成物
US8133861B2 (en) Systemic purine administration: modulating axonal outgrowth of central nervous system neurons

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period